PMV Pharmaceuticals
PMVP
73 hedge funds and large institutions have $2.34B invested in PMV Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 14 closing their positions.
157% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 14
113% more capital invested
Capital invested by funds: $1.1B → $2.34B (+$1.24B)
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
43% more funds holding
Funds holding: 51 → 73 (+22)
12.77% more ownership
Funds ownership: 72.59% → 85.36% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.7M |
| 2 |
BlackRock
New York
|
+$31.5M |
| 3 |
Alkeon Capital Management
New York
|
+$25.6M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$19.6M |
| 5 |
PA
Perceptive Advisors
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.4M |
| 2 |
Janus Henderson Group
London,
|
-$12.8M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$10.9M |
| 4 |
Millennium Management
New York
|
-$9.96M |
| 5 |
AG
Artal Group
Luxembourg
|
-$7.1M |
PMVP Hedge Fund Activity: Q4 2020 in Review
73 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2020, worth a combined $2.34B — up 113% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PMVP positions and 14 closed out — a net gain of 22 holders — while 19 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $44.7M. The largest seller was Wellington Management Group, cutting an estimated $13.4M.
- 73 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2020, up from 51 in Q3 2020.
- Funds reported $2.34B of PMV Pharmaceuticals stock for Q4 2020, up 113% quarter-over-quarter.
- 36 funds opened new PMV Pharmaceuticals positions in Q4 2020 and 14 closed out, a net change of +22 holders.
- The largest PMV Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $44.7M added.
- The largest PMV Pharmaceuticals seller in Q4 2020 was Wellington Management Group, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2020.